» Articles » PMID: 29671674

Pulmonary Hypertension in Chronic Lung Diseases: Comparison to Other Pulmonary Hypertension Groups

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2018 Apr 20
PMID 29671674
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age.

Citing Articles

Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with chronic lung disease and pulmonary hypertension.

Gayen S, Pescatore J, Bittner M, Naranjo M, Criner G, Weaver S BMC Pulm Med. 2025; 25(1):69.

PMID: 39923026 PMC: 11807298. DOI: 10.1186/s12890-025-03538-8.


Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.

Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K Int J Mol Sci. 2025; 26(2).

PMID: 39859549 PMC: 11765551. DOI: 10.3390/ijms26020835.


Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.

Nathan S, Stinchon Jr M, Atcheson S, Simone L, Nelson M J Manag Care Spec Pharm. 2025; 31(1-a Suppl):S2-S17.

PMID: 39745852 PMC: 11695281. DOI: 10.18553/jmcp.2025.31.1-a.s2.


Pulmonary hypertension associated with lung diseases.

Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E Eur Respir J. 2024; 64(4).

PMID: 39209469 PMC: 11525344. DOI: 10.1183/13993003.01200-2024.


Predictors of Mortality in Pulmonary Hypertension-Associated Chronic Lung Disease.

Pescatore J, Bittner M, DAlonzo G, Weaver S, Gayen S J Clin Med. 2024; 13(12).

PMID: 38929999 PMC: 11205208. DOI: 10.3390/jcm13123472.


References
1.
Nathan S, Shlobin O, Ahmad S, Koch J, Barnett S, Ad N . Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008; 76(3):288-94. DOI: 10.1159/000114246. View

2.
Hurdman J, Condliffe R, Elliot C, Swift A, Rajaram S, Davies C . Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2012; 41(6):1292-301. DOI: 10.1183/09031936.00079512. View

3.
Lettieri C, Nathan S, Barnett S, Ahmad S, Shorr A . Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3):746-52. DOI: 10.1378/chest.129.3.746. View

4.
Beland D, Viriot Durandal J . Aging in france: population trends, policy issues, and research institutions. Gerontologist. 2012; 53(2):191-7. DOI: 10.1093/geront/gns149. View

5.
Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, Gibbs J . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012; 186(8):790-6. DOI: 10.1164/rccm.201203-0383OC. View